NRG Oncology has pulled together a webpage to collate COVID-19 information for patients as well as for our researchers and research staff at our sites.
NRG-LU003 is a National Cancer Institute and NRG Oncology clinical trial to study clinical benefit of 2nd or 3rd generation ALK inhibitor in patients who develop progression on a second-generation ALK inhibitor. Treatment will be based on genetic changes identified on their tumor biopsy. NRG-LU003 will be comparing a number of ALK inhibitors including lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib. These targeted therapies may stop the growth of tumor cells by blocking some of the enzymes needed for cancer growth. NRG-LU003 will also be comparing the chemotherapy drugs pemetrexed plus cisplatin, and or carboplatin to test if chemotherapy may work equal, better or worse in these patients. More specific details about the treatment can be found in the FAQ section below.
More information about this particular study is located on ClinicalTrials.gov
Find a study location
Are you interested in joining this study?
Want more information?
Additional information for the NRG Oncology LU003 trial can be found in the Patient Study Brochure
Your healthcare team is the best source for information about your treatment options, including the ability to help you make decision to participate in cancer clinical trials. Be sure to take the information you find to your doctor for discussion about possible studies and for questions and concerns.
Please talk to your healthcare team to see if there are other clinical studies that you may be a good fit for. Click here if you would like to view a more detailed chart of other studies available.
Below, you can find FAQs about clinical research and this particular clinical trial.
At NRG Oncology, we focus on conducting clinical studies aimed to improve current cancer care practices and the lives of cancer patients. NRG Oncology partners with more than 1,300 member sites world-wide to research ways to improve treatment standards in the cancer community. Our organization is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trial's Network.